Table 3 HTA reports by ATC 1st level, anatomical main group, brand and product name of biosimilar
From: Health technology assessment of biosimilars worldwide: a scoping review
ATC Code | ATC – active substance (Chemical subgroup) | Number of HTA reports (%) | Biosimilar - brand name [product name] |
|---|---|---|---|
A (Alimentary tract and metabolism) 6 (8.57%) | |||
A10AE04 | Insulin glargine (Insulins and analogues for injection, long-acting) | 6 (8.57% | Abasaglar [LY2963016]; Basaglar [LY2963016] |
B (Blood and blood-forming organs) 10 (12.85%) | |||
B01AB05 | Enoxaparin (Heparin group) | 4 (5.71%) | Abenox Enoxaparin Becat [Crusia-AFT]; Crusia [Crusia-AFT]; Inhixa |
B03XA01 | Erythropoietin (Other antianaemic preparations) | 5 (7.14%) | Retacrit [SB309]; Binocrit [X575]; Abseamed [X575]; |
G (Genito-urinary system and sex hormones) 2 (2.86%) | |||
G03GA05 | Follitropin alfa (Gonadotropins) | 2 (2.86%) | Ovaleap [XM17]; Bemfola [AFOLIA-150]; |
H (Systemic hormonal preparationsa) 3 (4.29%) | |||
H01AC01 | Somatropin (Somatropin and somatropin agonists) | 2 (2.86%) | Omnitrope |
H05AA02 | Teriparatide (Parathyroid hormones and analogues) | 1 (1.43%) | Movymia [RGB-10] |
L (Antineoplastic and immunomodulating agents) 50 (71.42%) | |||
L01XC02 | Rituximab (Monoclonal antibodies) | 4 (5.71%) | Rixathon [GP2013]; Truxima [CT-P10]; Novex |
L01XC03 | Trastuzumab (Monoclonal antibodies) | 6 (8.57%) | Ogivri [Myl 1401O]; Trazimera [PF-05280014]; Ontruzant [SB3]; Kanjinti [ABP 980]; Herzuma [CT-P6] |
L01XC07 | Bevacizumab (Monoclonal antibodies) | 2 (2.86%) | Mvasi [ABP 215] |
L03AA13 | Pegfilgrastim (Colony stimulating factors) | 7 (10.00%) | Lapelga Fulphila [MYL-1401H]; Pelmeg [B121019]; Ziextenzo [LAEP2006]; Pelgraz [MYL-1401H]; |
L03AA02 | Filgrastim (Colony stimulating factors) | 5 (7.14%) | Biograstim [G-CSF] Ratiopharm [G-CSF]; Ratiograstim [XM02]; Tevagrastim [XM02]; Zarzio [EP2006]; Nivestim [Filgrastim-aaf]; Grastofil [Apo-filgrastim] |
L03AX13 | Glatiramer acetate (Other immunostimulants) | 1 (1.43%) | Glatect |
L04AB01 | Etanercept (TNF-α inhibitors) | 4 (5.71%) | Benepali [SB4]; Brenzys [SB4]; Erelzi [GP2015] |
L04AB02 | Infliximab (TNF-α inhibitors) | 17 (24.29%) | Remsima [CT-P13]; Inflectra [CT-P13]; Renflexis [SB2]; Flixabi [SB2]; Zessly [PF-06438179/GP1111] |
L04AB04 | Adalimumab (TNF-α inhibitors) | 4 (5.71%) | Hulio [FKB327]; Hyrimoz [GP2017]; Amgevita [ABP 501]; Imraldi [SB5] |